Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Ahead of Halliburton Company’s ( HAL - Analyst Report ) fourth-quarter results, we are maintaining our Neutral recommendation on the oilfield services behemoth.
Houston, Texas-based Halliburton is one of the largest oilfield service providers in the world, offering a variety of equipment, maintenance and engineering and construction services to the energy, industrial and government sectors. The company operates under two main segments: Completion and Production, and Drilling and Evaluation.
Halliburton recently reported in-line September quarter results, as higher activity in the international markets was offset by cost inflation. The company’s earnings per share from continuing operations (excluding special items) came in at 67 cents, matching the Zacks Consensus Estimate.
However, per share adjusted profits came sharply lower than the third quarter 2011 level of 94 cents (excluding an asset impairment charge) amid sluggish activity in its core North American operations. In particular, Halliburton continues to be plagued by a host of issues in this region, including a spike in the costs for guar gums, and Hurricane Isaac-related shutdowns.
However, the world's second-largest oilfield services firm after Schlumberger Limited ( SLB - Analyst Report ) is enjoying strong demand for its services in international markets and expects the trend to continue in the coming years. We have identified Latin America – offering enough shale development opportunities – as the important market in this regard.
Additionally, the company, which is scheduled to report fourth quarter and year-end 2012 results on January 25, remains in excellent financial health with some $2.0 billion in cash and a debt-to-capitalization ratio of around 24%. This helps Halliburton to capitalize on investment opportunities and offers options to make strategic acquisitions, thereby further improving growth visibility. Halliburton’s inexpensive valuation provides further support.
Considering these factors, we see the shares of Halliburton performing in line with the broader market. Our long-term Neutral recommendation is supported by a Zacks #3 Rank (short-term Hold rating).
Read the full reports :
Analyst Report on HAL
Analyst Report on SLB